Drugs / VALZIFLOCEPT
VALZIFLOCEPT
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT02605525 | Dec 2015 → Nov 2016 | IgA glomerulonephritis | Baxalta now part of Shire | Withdrawn | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VALZIFLOCEPT | ChEMBL registry synonym — accepted as the source's own label CHEMBL4298105 ↗ |
| Known as | SHP-652 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4298105 ↗ |
| Known as | SM101 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02605525 ↗ |
| Modality | Protein / enzyme biologic | “Human soluble recombinant Fcγ Receptor IIB” NCT02605525 ↗ |
| Route | Intravenous | “Intravenous Infusion With Human Soluble Recombinant Fc-gamma Receptor IIB (SM101/BAX 1810)” NCT02605525 ↗ |